Natco Pharma rose 2.75% to Rs 475.80 at 13:25 IST on BSE after consolidated net profit rose 10.65% to Rs 60.24 crore on 100.23% rise in total income to Rs 408.47 crore in Q4 March 2016 over Q4 March 2015.
The announcement was made after market hours yesterday, 26 May 2016.Meanwhile, the S&P BSE Sensex was up 239.74 points or 0.9% at 26,603.19
On BSE, so far 27,362 shares were traded in the counter as against average daily volume of 62,138 shares in the past one quarter. The stock hit a high of Rs 483.45 and a low of Rs 472 so far during the day. The stock had hit a record high of Rs 623.60 on 5 January 2016. The stock had hit a 52-week low of Rs 382.20 on 24 August 2015. The stock had underperformed the market over the past one month till 26 May 2016, falling 4.96% compared with Sensex's 1.38% rise. The scrip had also underperformed the market in past one quarter, gaining 9.65% as against Sensex's 13.87% rise.
The mid-cap company has equity capital of Rs 34.83 crore. Face value per share is Rs 2.
Natco Pharma said that the key driver for the accelerated revenue growth in Q4 March 2016 was the company's Hepatitis C portfolio of products in the domestic market.
Natco Pharma manufactures generic dosage forms, bulk actives and intermediates for the Indian and international markets.
Powered by Capital Market - Live News
